Arcutis Q2 net income turns to USD 15 million; revenue rises 59% year over year to USD 129.9 million - ARQT News | RalliesArcutis Q2 net income turns to USD 15 million; revenue rises 59% year over year to USD 129.9 million
A
ARQT• Regulatory update
- ZORYVE cream 0.3% gained FDA clearance for plaque psoriasis down to age 2; FDA set Feb. 23, 2027 action date for infant atopic dermatitis sNDA.
Q2 results and guidance
- Arcutis posted Q2 net income of USD 15 million, swinging from a net loss, as net product revenue rose 59% year over year to USD 129.9 million.
- Operating income improved to USD 16.43 million from an operating loss, while SG&A climbed to USD 82.14 million on higher personnel costs.
- R&D edged up to USD 20.36 million, while operating cash flow stayed positive at USD 12.6 million.
- 2026 net product sales guidance was raised to USD 525 million-USD 540 million.
•
